HIF1A and COVID-19: It has been demonstrated that dexamethasone decreases CA9 expression via the HIF-1α-dependent mechanism; thus, classical CA inhibitors (e.g., acetazolamide and methazolamide) could be used as an adjunctive treatment for COVID-19 patients; for example, acetazolamide treatment improved respiratory conditions in COVID-19 patients in a clinical study [15].